About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

NCT01420068·25 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Noden Pharma

Age

6–17

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Successful completion of study CSPP100A2365E1
Informed consent/ patient assent

You may not be if

Patients who did not successfully complete studies CSPP100A2365 and CSPP100A2365E1

The record

StatusCompleted

PhaseNo phase

Taking part106

StartedAug 2011

UpdatedMar 19, 2019

Conditions

Where25

Novartis Investigative Site
Birmingham, Alabama, United States
Novartis Investigative Site
Little Rock, Arkansas, United States
Novartis Investigative Site
Dalton, Georgia, United States

Clareo Health | 52-104 Week Off-therapy Second Extension to Study CSPP100A2365